Monoclonal antibodies in the clinic.

Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A (2002) 3.16

Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst. Proc Natl Acad Sci U S A (2003) 1.78

Immunology at the crossroads. As decades of research have resulted in few clinical applications, it is time to think about new research strategies to understand the workings of the immune system. EMBO Rep (2002) 1.52

Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis (2002) 1.51

Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol (2007) 1.44

Metrics for antibody therapeutics development. MAbs (2010) 1.21

Equipment characterization to mitigate risks during transfers of cell culture manufacturing processes. Cytotechnology (2015) 1.13

Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep (2015) 1.03

Probabilities of success for antibody therapeutics. MAbs (2009) 0.93

Mining human antibody repertoires. MAbs (2010) 0.92

Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics. J Biol Chem (2013) 0.88

Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody. Int Immunopharmacol (2007) 0.84

IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA. MAbs (2012) 0.84

Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers. BMC Cancer (2004) 0.80

4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland. MAbs (2009) 0.77

Second International Conference on Accelerating Biopharmaceutical Development: March 9-12, 2009, Coronado, CA USA. MAbs (2009) 0.75

Biologic therapies: what and when? J Clin Pathol (2007) 0.75